PRUSOGLIPTIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H25FN4O2
Molecular Weight	324.3937
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(CC(=O)N1CCCC1)NCC(=O)N2C[C@@H](F)C[C@H]2C#N

InChI

InChIKey=VQKSCYBKUIDZEI-STQMWFEESA-N

InChI=1S/C16H25FN4O2/c1-16(2,8-14(22)20-5-3-4-6-20)19-10-15(23)21-11-12(17)7-13(21)9-18/h12-13,19H,3-8,10-11H2,1-2H3/t12-,13-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20483603
Curator's Comment: description was created based on several sources, including http://www.clinicalleader.com/doc/scinopharm-and-national-health-research-0001

DBPR-108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM; no inhibition on DDP8 and DPP9, which is in phase I clinical trial as a potential treatment of type 2 diabetes.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dipeptidyl peptidase IV 37 Target ID: CHEMBL4653 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20483603	Inhibitor 8297		15.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 259 Sources: http://www.clinicalleader.com/doc/scinopharm-and-national-health-research-0001	Palliative		Phase I 428	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32338063 Page: p.8	unhealthy, 52.59 n = 69 Health Status: unhealthy Condition: Type 2 diabetes Age Group: 52.59 Sex: M+F Population Size: 69 Sources: https://pubmed.ncbi.nlm.nih.gov/32338063 Page: p.8	Sources: https://pubmed.ncbi.nlm.nih.gov/32338063 Page: p.8

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P008U2D	https://www.1pchem.com/search?query=1P008U2D
AChemBlock	P50908	http://www.achemblock.com/catalogsearch/result/?q=P50908
BLD Pharm	BD629964	http://www.bldpharm.com/search/Search.html?keyword=BD629964
Chem Scene	CS-3825	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-3825
ChemShuttle	157284	https://www.chemshuttle.com/catalogsearch/result/?q=157284
Lab Network	LN01342441	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01342441
MedChem Express	HY-12528	https://www.medchemexpress.com/search.html?q=HY-12528&ft=&fa=&fp=
MolPort	MolPort-046-416-909	https://www.molport.com/shop/molecule-link/MolPort-046-416-909
Molnova	M10635	https://www.molnova.com/en/serch-list.html?keywords=M10635
eMolecules	275136849	https://orderbb.emolecules.com/search/#?query=275136849
eMolecules	302053879	https://orderbb.emolecules.com/search/#?query=302053879
eMolecules	53744848	https://orderbb.emolecules.com/search/#?query=53744848
mcule	MCULE-5047272043	https://mcule.com/MCULE-5047272043/
mcule	MCULE-9429260794	https://mcule.com/MCULE-9429260794/

PubMed

Title	Date	PubMed
(2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.	2010 Jun 15	20483603

Patents

Sample Use Guides

In Vivo Use Guide

DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

PRUSOGLIPTIN

Official Name

English

prusogliptin [INN]

Common Name

English

DBPR-108

Code

English

(2S,4S)-4-FLUORO-1-(((2-METHYL-4-OXO-4-(PYRROLIDIN-1- YL)BUTAN-2-YL)AMINO)ACETYL)PYRROLIDINE-2-CARBONITRILE

Systematic Name

English

2-PYRROLIDINECARBONITRILE, 1-(2-((1,1-DIMETHYL-3-OXO-3-(1-PYRROLIDINYL)PROPYL)AMINO)ACETYL)-4-FLUORO-, (2S,4S)-

Systematic Name

English

(2S,4S)-1-(2-((1,1-DIMETHYL-3-OXO-3-(1-PYRROLIDINYL)PROPYL)AMINO)ACETYL)-4-FLUORO-2-PYRROLIDINECARBONITRILE

Systematic Name

English

Code System Code Type Description

INN

11627